Cowen & Co. analyst Boris Peaker maintained a Hold rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $43. The company’s shares opened today at $46.29.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.8% and a 41.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Molecular Templates Inc, and CytomX Therapeutics Inc.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $53.22, implying a 15.0% upside from current levels. In a report issued on May 2, Stifel Nicolaus also upgraded the stock to Hold with a $45 price target.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals’ market cap is currently $1.93B and has a P/E ratio of 266.72. The company has a Price to Book ratio of 5.88.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PCRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
